secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001104659-24-060715
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia Q1 net loss widens to $40.9M; YUTREPIA legal barriers removed
----------------------------------------------------------------------

- Net loss $40.9M ($0.54/share) vs $11.7M ($0.18) in Q1 2023; revenue fell 33% to $3.0M on lower Treprostinil Injection sales.
- Cash $157.9M after $100M gross proceeds from common stock private placement and RIFA fourth amendment in January 2024.
- G&A expenses surged 160% to $20.2M, driven by $3.1M higher litigation costs and $5.9M personnel rise.
- All legal barriers to FDA approval of YUTREPIA removed; awaiting ruling on preliminary injunction in new UTHR patent suit.
- ASCENT study of YUTREPIA in PH-ILD enrolling; L606 liposomal treprostinil data to be presented at ATS 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924060715/0001104659-24-060715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924060715/tm2414358d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer